On June 10, Defeat Duchenne Canada welcomed the news that Italfarmaco’s New Drug Submission for Duvyzat (givinostat), a potential treatment for Duchenne muscular dystrophy, has been accepted by Health Canada for Priority Review.
Health Canada’s Priority Review is a faster review process for new drugs that may address serious or life-threatening conditions or significantly improve patients’ lives. This designation allows Health Canada to evaluate promising therapies more quickly, which could help make new treatment options available to Canadians sooner if approved.
Duvyzat works differently from many other Duchenne treatments. It targets enzymes involved in inflammation and scarring in muscle tissue, processes that contribute to muscle damage over time in people living with Duchenne. By helping to reduce these effects, Duvyzat may help preserve muscle health and slow disease progression.
Importantly, Duvyzat’s approach is not dependent on a specific dystrophin gene mutation. This means it has the potential to benefit a broad range of people living with Duchenne muscular dystrophy, regardless of the genetic mutation causing their disease.
This is encouraging news for the Canadian Duchenne community and reflects the important contributions of Canadian patients, families, researchers, and clinicians to the development of potential new therapies for Duchenne.
Health Canada’s Priority Review process is expected to take approximately 180 days. Following this review, Health Canada will decide whether Duvyzat can be approved for use in Canada to treat Duchenne muscular dystrophy.
If Duvyzat is approved in Canada, Defeat Duchenne Canada will work closely with the Duchenne community, healthcare professionals, regulators, and policymakers to support timely and equitable access to this new treatment. We remain committed to ensuring that eligible Canadians can access new treatment options as quickly as possible.
Read the press release below to learn more.
Want to know more about Duchenne Research?
Scientists and medical experts have been tirelessly pursuing diverse approaches to defeat Duchenne muscular dystrophy. From tackling the root cause to alleviating symptoms, the field of research is vast and promising. Explore the various strategies being developed and tested, and gain insights into the future of muscular dystrophy treatment: